Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patientsArticle Published on 2023-05-012023-07-09 Journal: Journal of cancer research and clinical oncology [Category] COVID19(2023년), [키워드] Cancer COVID-19 Hesitancy SARS-CoV-2 Tolerability vaccination. [DOI] 10.1007/s00432-022-04099-7 PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimodArticle Published on 2022-12-012022-11-15 Journal: Journal of Neurology [Category] COVID19(2023년), SARS, 진단, [키워드] binding antibody unit BNT162b2 mRNA BNT162b2 mRNA vaccine booster dose collected Control COVID-19 COVID-19 vaccine dose expressed fingolimod HCs humoral Humoral response IgG IgG antibody IgG level Laboratory mRNA mRNA vaccine Multiple multiple sclerosis Ocrelizumab Ocrelizumab. of BNT162b2 Patient positive predict quantified reported SARS-CoV-2 sclerosis serum sample severe adverse event socio-demographic threshold Tolerability treated Trimeric spike protein Vaccine vaccine dose variable [DOI] 10.1007/s00415-022-11296-4 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
COVAD survey 2 long-term outcomes: unmet need and protocolArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 치료제, [키워드] adverse event antiviral drug approach approved Autoimmune diseases baseline booster doses cohorts COVID-19 COVID-19 infection COVID-19 vaccine disease Effect effort groups help Heterologous immune modulation Immunity IMPROVE long-term adverse effects pandemic protocol reduce registries risk syndrome synergistic Tolerability translation unmet need vaccination vaccination. Vaccine while [DOI] 10.1007/s00296-022-05157-6 PMC 바로가기
Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trialArticle Published on 2022-11-032022-11-16 Journal: Journal of Translational Medicine [Category] 비임상, [키워드] 1:1 Administered administration adverse event age Analysis animal model Anti-inflammatory assigned baseline Borg change changes in Chronic diseases clinical trial clinically COVID COVID pneumonia COVID-19 defined Diagnosis discharged double-blind Dyspnea Effect effective Efficacy Endpoint enrolled evaluated female female gender FEV first symptom FVC impairment increase in indicated Infection initial LLC lung damage Lung fibrosis Lung function Lungs mMRC moderate NCT04527354 offer past medical history Patient patients pharmacological treatment Placebo placebo group placebo-controlled clinical trial placebo-controlled trial Post-COVID rehabilitation predicted Prevent Primary outcome proportion pulmonary dysfunction pulmonary fibrosis Pulmonary function questionnaire Randomized Randomly reduction in Registered rehabilitation risk factor Russia SARS-CoV-2 secondary shown significant decrease significant difference stratified Support Symptoms Tolerability Treamid. Treatment Trial was done women [DOI] 10.1186/s12967-022-03660-9 PMC 바로가기
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy AdultsArticle Published on 2022-10-182022-11-15 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CL acid administration adverse event affected agent Antiviral assessment AUC C max COVID-19 demonstrated dose doses drug-drug interaction Effect ensitrelvir first-in-human Food Intake geometric increase in Infection inhibitor Japanese mild in severity MOST novel oral dosing P450 participant Participants participants with SARS-CoV-2 pharmacokinetics phase 1 study Placebo plasma proportionality protease Protease inhibitor protease inhibitor. Randomized reduced resolved Safety SARS-CoV-2 selective single dose substrate T max Tolerability Treatment viral replication [DOI] 10.1128/aac.00632-22 PMC 바로가기
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal ImpairmentArticle Published on 2022-10-012022-11-15 Journal: Clinical Pharmacology and Therapeutics [Category] 치료제, [키워드] 24 hour adjusted Administered adverse event adverse outcome assessments Chronic kidney disease clearance coronavirus disease COVID-19 decrease dose dose reduction Effect eliminated evaluated exhibited geometric geometric mean ratio glomerular filtration rate group increased risk kidney laboratory measurements Mild mild in severity moderate Nirmatrelvir oral participant Patient patients with moderate pharmacokinetics Phase I plasma plasma concentration positively correlated progression reducing renal renal function renal impairment risk Ritonavir severe disease severe renal impairment systemic Tolerability vital signs [DOI] 10.1002/cpt.2688 PMC 바로가기
Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] SARS, 진단, [키워드] 1:1 binding domain Booster vaccine cell-mediated response clinical Controlled trial COVID COVID-19 COVID-19 vaccination COVID-19 vaccine death develop disease severity dose Effectiveness Efficacy ENhance hospitalisation humoral hypothesise IgG immune cell population immunological Immunosuppression IMPROVE include increased risk Intervention kidney transplant recipient kidney transplant recipients Kidney transplantation live SARS-CoV-2 Modification mTOR inhibitor multicentre neutralisation New outcome participant Prednisolone Primary outcome proportion Protective protective immunity public health randomised randomised controlled trial Rapamycin recipient reduce reduced regimen registry responses SARS-CoV-2 SARS-CoV-2 vaccine secondary serological Sirolimus Standard of care Study protocol Tolerability Trial vaccination vaccination. Vaccine vaccine response virus [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational studyArticle Published on 2022-09-022022-10-06 Journal: Lancet Reg Health Eur [Category] 진단, [키워드] Adverse adverse events analysed AZD1222 Biogen Bristol Clinical data courses COVID-19 Deterioration effective fatigue Frequency Gender Germany headache Health impairment injection long-lasting longitudinal men Merck Serono Multiple multiple sclerosis Mylan Novartis occurred offer opposite Pain participated Patient reaction real-world data registry reported resulting Roche Sanofi SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine sclerosis severe COVID-19 disease Society Sociodemographic stratified Symptoms Tolerability United Kingdom vaccination Vaccination reaction Vaccination reaction. Vaccine women worsened [DOI] 10.1016/j.lanepe.2022.100502 PMC 바로가기 [Article Type] Article